Efficacy and Safety of Trametinib Therapy for Complex Lymphatic Malformations

Area of Science:

• Pediatric Oncology
• Vascular Anomalies
• Pharmacology

Background:

• Complex lymphatic malformations, including kaposiform lymphangiomatosis (KLA) and generalized lymphatic anomaly (GLA), present significant clinical challenges in pediatric patients.
• Current treatment options for KLA and GLA are limited, necessitating the exploration of novel therapeutic strategies.

Purpose of the Study:

• To evaluate the safety and efficacy of trametinib as a treatment for pediatric patients diagnosed with KLA and GLA.
• To assess the clinical and radiographic outcomes in patients receiving trametinib therapy.

Main Methods:

• A cohort of five pediatric patients with KLA/GLA received trametinib treatment.
• Clinical parameters, including coagulopathy markers (platelet count, D-dimer), and radiographic responses were monitored.
• Genomic analysis was performed to detect NRAS proto-oncogene mutations.

Main Results:

• All patients demonstrated significant clinical improvement, with resolution of coagulopathy.
• Platelet counts increased by 54%-362% and D-dimer levels decreased by over 91%.
• Eighty percent of patients achieved partial radiographic response with minimal toxicity (one Grade 2 rash). NRAS mutations were present in 80% but not required for benefit.

Conclusions:

• Trametinib represents an effective and safe first-line therapy for pediatric KLA and GLA.
• Clinical benefit was observed irrespective of NRAS mutation status, broadening its potential applicability.
• Further investigation into trametinib for lymphatic malformations is warranted.